Stock ZICC ZICCUM AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ziccum AB

Equities

ZICC

SE0011415595

Pharmaceuticals

Delayed Nasdaq Stockholm
Other stock markets
 03:33:04 2024-04-30 am EDT 		5-day change 1st Jan Change
6 SEK -0.66% Intraday chart for Ziccum AB -4.76% -21.67%
Mar. 14 Ziccum AB Inhalable mRNA/LNP Project Confirms Excellent Properties Obtained by LaminarPace CI
Mar. 01 Ziccum AB and project partner Zurich institute of Applied Sciences Updates LaminarPace Simulation Project Progress and Findings CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 36 83.4 260.3 102.8 34.24 105.8
Enterprise Value (EV) 1 25.46 81.34 228.7 92.5 12.72 103.6
P/E ratio -4.73 x -9.56 x -13.2 x -4.83 x -1.19 x -4.94 x
Yield - - - - - -
Capitalization / Revenue 88.7 x 128 x 52,066 x 20,554 x 2,014 x 16.7 x
EV / Revenue 62.7 x 124 x 45,742 x 18,499 x 748 x 16.4 x
EV / EBITDA -6.39 x -9.37 x -13.6 x -4.56 x -0.46 x -5.09 x
EV / FCF -8.81 x -15.6 x -15.9 x -6.33 x -0.55 x -9.05 x
FCF Yield -11.3% -6.39% -6.28% -15.8% -183% -11%
Price to Book 3 x 4.86 x 7.16 x 3.88 x 1.17 x 12.3 x
Nbr of stocks (in thousands) 6,000 6,000 9,606 9,806 13,806 13,806
Reference price 2 6.000 13.90 27.10 10.48 2.480 7.660
Announcement Date 4/15/19 4/16/20 3/23/21 3/24/22 2/17/23 4/15/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.406 0.654 0.005 0.005 0.017 6.318
EBITDA 1 -3.984 -8.678 -16.84 -20.27 -27.58 -20.34
EBIT 1 -4.211 -8.721 -17.24 -21.12 -28.96 -21.56
Operating Margin -1,037.19% -1,333.49% -344,700% -422,320% -170,323.53% -341.25%
Earnings before Tax (EBT) 1 -4.571 -8.723 -17.29 -21.14 -28.79 -21.41
Net income 1 -4.571 -8.723 -17.29 -21.14 -28.79 -21.41
Net margin -1,125.86% -1,333.79% -345,780% -422,720% -169,341.18% -338.9%
EPS 2 -1.270 -1.454 -2.056 -2.170 -2.090 -1.551
Free Cash Flow 1 -2.89 -5.201 -14.36 -14.6 -23.26 -11.45
FCF margin -711.7% -795.24% -287,152.5% -292,020% -136,805.15% -181.2%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/15/19 4/16/20 3/23/21 3/24/22 2/17/23 4/15/24
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 10.5 2.06 31.6 10.3 21.5 2.14
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -2.89 -5.2 -14.4 -14.6 -23.3 -11.4
ROE (net income / shareholders' equity) -66.7% -59.8% -64.6% -63.9% -97.5% -113%
ROA (Net income/ Total Assets) -36.2% -35% -37.1% -34.5% -51.6% -55.8%
Assets 1 12.61 24.95 46.57 61.29 55.82 38.34
Book Value Per Share 2 2.000 2.860 3.790 2.700 2.120 0.6200
Cash Flow per Share 2 1.760 0.3400 3.500 1.120 1.660 0.2200
Capex 1 0.28 0.15 3.8 6.42 3.9 0.14
Capex / Sales 68.97% 22.63% 76,060% 128,480% 22,929.41% 2.15%
Announcement Date 4/15/19 4/16/20 3/23/21 3/24/22 2/17/23 4/15/24
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
ZICCUM AB Stock Ziccum AB
-21.67% 8.5M
CSL LIMITED Stock CSL Limited
-3.45% 87.17B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.97% 40.1B
UCB Stock UCB
+58.05% 25.12B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.82% 15.59B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-8.82% 12B
INCYTE CORPORATION Stock Incyte Corporation
-16.29% 11.8B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-41.58% 11.8B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+7.42% 8.81B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-10.29% 8.24B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. ZICC Stock
  4. Financials Ziccum AB